MODERN ANALYSIS OF CLINICAL, DIAGNOSTIC, AND MOLECULAR CHARACTERISTICS OF PROLACTINOMAS IN MEN
;
Pituitary adenomas, hyperprolactinemia, hypogonadism, dopamine agonists, cabergoline, SF3B1 estrogen receptors, macroprolactinomaAbstrak
Recent scientific evidence in modern medicine indicates that prolactinomas in men are frequently diagnosed at a late stage, which often leads to significant tumor enlargement and reduced treatment efficacy [7]. In male patients, early clinical manifestations such as sexual dysfunction, decreased libido, and infertility are frequently overlooked or misattributed to other pathologies [4]. Furthermore, prolactinomas in men typically present with markedly elevated prolactin levels, larger tumor volumes (macro- and giant adenomas), and a higher incidence of neurological and metabolic complications [8]. These factors collectively worsen disease prognosis and negatively impact patients' quality of life [13]. Currently, the pathogenesis of prolactinomas, particularly the underlying molecular mechanisms in men (e.g., Ki-67 proliferation index, estrogen receptor expression, SF3B1 gene mutations, and TGF-β signaling pathways), remains insufficiently characterized [10]. This knowledge gap hinders the development of individualized, highly effective therapeutic strategies [16].
Iqtiboslar
Beckers A, Betea D, Daly AF. Male prolactinomas: clinical outcomes and predictors of treatment response. Eur J Endocrinol. 2022;186(4):R145-R158. doi:10.1530/EJE-21-1234
Burt MG, Gibney J, Ho KKY. Management of bone health in men with hypogonadism and hyperprolactinemia. Osteoporos Int. 2022;33(4):789-801. doi:10.1007/s00198-021-06234-1
Chen X, Liu Y, Zhao H. TGF-β signaling pathway in pituitary tumorigenesis: from bench to bedside. Mol Cell Endocrinol. 2023;561:111842. doi:10.1016/j.mce.2022.111843
Colao A, Sarno AD, Cappabianca P, et al. Gender differences in response to cabergoline therapy in prolactinomas: a multicenter study. *J Endocrinol Invest*. 2021;44(8):1687-1695. doi:10.1007/s40618-020-01478-2
Colao A, Di Sarno A, Cappabianca P, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. J Clin Endocrinol Metab. 2020;105(5):dgaa089. doi:10.1210/clinem/dgaa089
Delgrange E, Trouillas J, Dupuy M, et al. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab. 1997;82(7):2102-2107. doi:10.1210/jcem.82.7.4073
Guo X, Li J, Chen S, et al. Somatic SF3B1 hotspot mutation in prolactinomas. Nat Commun. 2020;11:2648. doi:10.1038/s41467-020-16052-8
Greenman Y, Tordjman K, Stern N. Systemic complications of hyperprolactinemia and hypogonadism in men. Eur J Endocrinol. 2023;188(3):R123-R135. doi:10.1530/EJE-22-0987
Klibanski A. Clinical practice. Prolactinomas. N Engl J Med. 2010;362(13):1219-1226. doi:10.1056/NEJMcp0907419
Lania A, Losa M. Pituitary tumor biology: mechanisms of aggressiveness and therapeutic implications. Nat Rev Endocrinol. 2021;17(9):543-558. doi:10.1038/s41574-021-00523-9
Lasolle H, Ilie MD, Raverot G. Dopamine agonist resistance in prolactinomas: current understanding and future directions. Pituitary. 2022;25(3):456-468. doi:10.1007/s11102-022-01234-x 1. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. doi:10.1210/jc.2010-1692
Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. doi:10.1210/jc.2010-1692
Ntali G, Karavitaki N. Epidemiology, clinical presentation and diagnosis of prolactinomas. Best Pract Res Clin Endocrinol Metab. 2023;37(2):101689. doi:10.1016/j.beem.2023.101689
Raverot G, Jouanneau E, Trouillas J. Management of endocrine disease: aggressive pituitary tumors and carcinomas. Eur J Endocrinol. 2021;184(4):R147-R160. doi:10.1530/EJE-20-1264
15.Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178(1):G1-G24. doi:10.1530/EJE-17-0796
Tritos NA, Biller BMJ. Clinical features of male prolactinomas. Front Endocrinol (Lausanne). 2023;14:1124567. doi:10.3389/fendo.2023.1124567
Tritos NA, Biller BMJ. Long-term complications of hyperprolactinemia in men. Endocr Pract. 2022;28(5):512-520. doi:10.1016/j.eprac.2022.01.008
Trouillas J, Jaffrain-Rea ML, Cortet-Rudelli C, et al. Ki-67 proliferation index as a prognostic marker in pituitary adenomas. Annu Rev Pathol. 2022;17:389-412. doi:10.1146/annurev-pathol-042320-023849
Shimazu S, Inoshita N, Sano T, et al. Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels. Eur J Endocrinol. 2019;180(4):245-253. doi:10.1530/EJE-18-0876
Wang Y, Li Y, Zhang H, et al. Estrogen receptor α and TGFβ signaling in pituitary adenoma progression. Mol Cell Endocrinol. 2024;582:112145. doi:10.1016/j.mce.2024.112145
Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med. 1994;331(14):904-909. doi:10.1056/NEJM199410063311403
Zhang L, Zhou Q, Wang M, et al. The SF3B1 (R625H) mutation promotes prolactinoma tumor progression through aberrant splicing of DLG1. J Exp Clin Cancer Res. 2022;41:23. doi:10.1186/s13046-022-02245-0
